Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fadi Towfic

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Blood|January 30, 2019
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myelomaAnjan Thakurta, Maria Ortiz, Pedro Blecua, et al.
Gastroenterology|October 1, 2013
Genetic variants synthesize to produce paneth cell phenotypes that define subtypes of Crohn's diseaseKelli L VanDussen, Ta-Chiang Liu, Dalin Li, et al.
Blood|January 14, 2021
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myelomaSarah Gooding, Naser Ansari-Pour, Fadi Towfic, et al.
Journal of Neuroimmunology|December 30, 2015
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its compositionTal Hasson, Sarah Kolitz, Fadi Towfic, et al.
Scientific Reports|May 23, 2015
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoidsSarah Kolitz, Tal Hasson, Fadi Towfic, et al.
Blood|July 19, 2022
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myelomaSarah Gooding, Naser Ansari-Pour, Mohammad Kazeroun, et al.
Human Molecular Genetics|July 29, 2016
Pridopidine activates neuroprotective pathways impaired in Huntington DiseaseMichal Geva, Rebecca Kusko, Holly Soares, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2016
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptorJoel Kaye, Victor Piryatinsky, Tal Birnberg, et al.
Blood|January 25, 2020
Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agentAlberto Risueño, Patrick R Hagner, Fadi Towfic, et al.
The Lancet. Gastroenterology & Hepatology|June 2, 2025
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trialBrian G Feagan, Bruce E Sands, Corey A Siegel, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Blood|January 30, 2019
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myelomaAnjan Thakurta, Maria Ortiz, Pedro Blecua, et al.
Gastroenterology|October 1, 2013
Genetic variants synthesize to produce paneth cell phenotypes that define subtypes of Crohn's diseaseKelli L VanDussen, Ta-Chiang Liu, Dalin Li, et al.
Blood|January 14, 2021
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myelomaSarah Gooding, Naser Ansari-Pour, Fadi Towfic, et al.
Journal of Neuroimmunology|December 30, 2015
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its compositionTal Hasson, Sarah Kolitz, Fadi Towfic, et al.
Scientific Reports|May 23, 2015
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoidsSarah Kolitz, Tal Hasson, Fadi Towfic, et al.
Blood|July 19, 2022
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myelomaSarah Gooding, Naser Ansari-Pour, Mohammad Kazeroun, et al.
Human Molecular Genetics|July 29, 2016
Pridopidine activates neuroprotective pathways impaired in Huntington DiseaseMichal Geva, Rebecca Kusko, Holly Soares, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2016
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptorJoel Kaye, Victor Piryatinsky, Tal Birnberg, et al.
Blood|January 25, 2020
Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agentAlberto Risueño, Patrick R Hagner, Fadi Towfic, et al.
The Lancet. Gastroenterology & Hepatology|June 2, 2025
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trialBrian G Feagan, Bruce E Sands, Corey A Siegel, et al.
Pageof 4